D.E. Ryspayeva

National Cancer Institute, MH of Ukraine, Kyiv, Ukraine

PREDICTIVE AND PROGNOSTIC POTENTIAL OF CD44 AND CD24 EXPRESSION IN PRIMARY TUMOUR AND AFTER CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER

Aim: to evaluate prognostic and predictive value of surface-cells markers — CD44 and CD24 in the primary tumour tissue and after neoadjuvant chemotherapy (NACT) in different groups of patients of breast cancer (BC). **Object and methods:** *specimens of the primary tumour and specimens after chemotherapy in 106 patients with invasive BC. The observed patients were treated at the National Cancer Institute. Immunohistochemical staining for CD44 and CD24 was performed in tumour specimens. The survival analysis was performed depending on the clinical and pathological data and the expression of markers CD44, CD24, CD44$^+$/CD24$^-$, CD44$^+$/CD24$^+$.* **Results:** *different expressions of markers in the primary tumour tissue and after NACT were detected. An increase of the expression of CD44$^+$ and CD44$^+$/CD24$^-$ has been noted in tumour tissue after NACT, which may play a role in the development of chemoresistance and the possible mechanism of relapse of invasive BC. The prognostic value of triple negative subtype of BC, tumour size, coexpression of noninvasive CD44$^+$/CD24$^+$ cells was revealed in the Cox regression model.* **Conclusion:** *the differing expression of surface-cells markers in the primary tumour and after NACT may reflect intratumoral heterogeneity of the BC and the possible development of chemoresistance. Triple negative subtype and tumour size were revealed as the risk factors associated with survival. Markers CD44 and CD24 were insufficient factors to determine the prognosis.*

INTRODUCTION

Breast cancer (BC) is the main cause of women's death from cancer [1]. After radical treatment of patients with BC some of them have relapses and metastases. According to the theories their appearance is associated with cancer stem cells (CSC) — small population of stem cells which is the cause of growth of tumour [2] and resistance to radiation therapy [3] and chemotherapy [4].

The majority of current investigations have identified a subpopulation of BC stem cells through surface-cell markers — CD44 and CD24 [5, 6]. One of the most investigated CSC is the phenotype CD44$^+$/CD24$^-$, but its clinical significance remains controversial. This phenotype is associated with more aggressive clinical and pathological data of BC [7], it is more common in patients with distant metastasis [8, 9] and it has a link with three-negative [10] and basal type of tumour [11, 12]. The correlation of immunophenotype CD44$^+$/CD24$^-$ with resistance to anthracyclines is emphasized in some researches [13, 14], but the main mechanisms are still unknown. Investigations to find CSC markers predicting drug resistance continue nowadays.

CD24 expression was detected in various types of carcinoma while it is seldom expressed in normal tissues [15]. Some research reports indicate that low CD24 expression is a characteristic biomarker, which promotes the initiation and progression of tumour process [16], as well as

demonstrates the resistance to doxorubicin [13]. The other ones show that high CD24$^+$ expression is considered to be an unfavorable prognostic factor of BC, associated with short-term disease-free survival (DFS) and may be a marker of sensitivity to adjuvant chemotherapy [17, 18]. Besides CD24 expression was significantly correlated with the aggressive HER2-positive status of BC [19] and with drug resistance in the HER2/neu expression [20].

CD44 is a well-known transmembrane glycoprotein. It is a contributing factor to carcinogenesis and a progression to a variety of neoplasms [21]. Previous investigations have demonstrated that aberrant expression of CD44 is associated with invasion, metastasis and has a negative effect on DFS in patients with HER2 expression or a basal-like BC [21]. But Horiguchi [22] substantiated that DFS is higher with high expression of CD44. At the same time, the other authors do not observe any differences in clinical outcomes and survival in regards to the expression of CD44 and CD24 [19].

Thus, numerous investigations about the role of CD44, CD24 in carcinogenesis and contradictory data of their prognostic significance have determined our interest for further research. In addition, the predictive potential of these biomarkers has not been sufficiently studied. Therefore, our task is to evaluate prognostic and predictive value of biomarkers CD44 and CD24 in primary tumour and after chemotherapy in different groups of patients with BC.

MATERIALS AND METHODS

Specimens of the primary tumour and specimens after chemotherapy in patients with invasive BC have been studied separately. The observed patients were treated at the National Cancer Institute from 2008 to 2013.

The criteria for inclusion in this research were the following: women samples; histologically confirmed BC; tumour samples available for study. The medical records, pathology reports of the patients for obtaining clinical information were analyzed. The disease stage was classified according to the TNM AJCC categories (6th edition). A local ethical committee approved the study protocol.

From 130 cases of BC included in this research specimens only 106 patients were suitable for staining and informative for immunohistochemical (IHC) results. Patients were divided into two groups: group 0 — the patients with directly examined the primary tumour; group 1 — the patients after neoadjuvant chemotherapy (NACT). The median of observation was 48.5 months (interquartile range Q1 = 36.5 months, Q3 = 63.5 months).

Clinical and pathological characteristics of patients are indicated in Table 1. NACT was conducted mainly to patients up to 50 years old (the difference between the groups by age is statistically significant, p = 0.02). The median age for group 0 was 52.5 years old, for group 1 — 47 years old.

The distribution of disease stages according to T and N categories between the groups was different (p < 0.05). It was caused by NACT criterion for grouping. Among the patients having operative treatment immediately, 82.5% of them had early stages of BC, and 19.2% of the patients had the IIIA stage. It is due to staging of disease after surgery considering the regional lymph node involvement. NACT was performed for the majority of patients (66.7%) with the locally advanced BC in accordance with standard treatment protocols. Regimens of NACT included mainly anthracyclines (90.7%) and paclitaxel were used in 9.3% of cases. The distribution of tumour phenotype did not reveal a statistically significant difference between the groups (p = 0.75). The majority of patients were patients with luminal tumour subtypes in both groups.

IHC analysis. The original hematoxylin-eosin-stained patients' glasses in the retrospective sample were examined and noted by the pathomorphologist for further analysis of cell surface markers. Specific primary anti-CD44 antibodies (polyclonal rabbit antibodies, 1:100, Thermo Scientific, USA) and CD24 (SN3, monoclonal mouse antibodies, 1:200, Thermo Scientific, USA) were used for IHC staining according to the methodology described in previous research [23]. Two pathologists who weren't aware the clinical outcomes of patients independently carried out assessment of staining results. IHC surrogate panel (ER, PgR, HER2) was used to determine the subtypes of BC [24].

Statistical analysis. DFS was defined as a period from the date of operations to the documented date of recurrence and/or distant metastases. Overall survival was defined as a number of months from the diagnosis to the date of death. Censored overall survival was taken into account when the date of death of a patient was unknown and the date of the last observation was the indication point. Differences in the frequencies of the main clinical-pathological parameters and subtypes were analyzed using the chi-square test. Survival curves were constructed using the Kaplan — Meier method and ranking test was used to compare the meaning of survival rates by subtypes. Cox model was used for multivariate analysis in order to predict the survival relationship with patient age, tumour size, lymph node involvement, various subtypes of BC, NACT and cell-surface marker content. Hazard ratio (HR) and its 95% confidence interval (CI) were calculated to assess the degree of relationship.

Table 1

Clinical and pathological characteristic of patients in groups

Characteristics		Absolute value (%)		p
		Group 0 (n = 52)	Group 1 (n = 54)	
Age (X ± SD), years old		50.6 ± 10.5	46.2 ± 9.4	0.02
Age range, years		27–71	28–64	
Median, years		52.5	47	
25–75 quartiles, years		42.5–58.5	30–55	
Stage (AJCC)	I	4 (7.7)	0	< 0.001
	IIA	20 (38.5)	6 (11.1)	
	IIB	18 (34.6)	22 (40.7)	
	IIIA	10 (19.2)	25 (46.3)	
	IIIB	0 (0.0)	1 (1.9)	
Category T	1	6 (11.5)	2 (3.7)	0.002
	2	46 (88.5)	40 (74.1)	
	3	0 (0.0)	10 (18.5)	
	4	0 (0.0)	2 (3.7)	
Category N	0	22 (42.3)	9 (16.7)	0.008
	1	20 (38.5)	24 (44.4)	
	2	10 (19.2)	21 (38.9)	
Subtype	Luminal A	19 (36.5)	17 (31.5)	0.75
	Luminal B (HER2−)	18 (34.6)	19 (35.2)	
	Luminal B (HER2+)	1 (1.9)	4 (7.4)	
	Triple negative BC (TNBC)	12 (23.1)	12 (22.2)	
	HER2/neu expression	2 (3.9)	2 (3.7)	

A critical level of significance was chosen at p < 0.05. The analysis was performed using statistical software packages MedCalc 17.9.2 (MedCalc Software bvba, 1993–2017).

RESULTS AND COMMENTS

Analysis of expression of immunophenotypes CD44, CD24, CD44+/CD24−, CD44+/CD24+ in different groups of patients. IHC analysis of the expression of CD44, CD24, CD44+/CD24− as presumed CSC was performed in 106 patients with an invasive BC in order to identify the association of these markers with the treatment (Table 2).

There was no statistically significant difference for biomarker of the CD24 (p = 0.16) in the groups of patients with and without NACT. But there was a tendency (p = 0.08) to increase CD44+ expression in the tumour tissue after NACT (59.3% of cases), as there was a predominant lack of CD44 expression (59.6% of cases) in the primary tumour tissue.

Table 2

Association of immunophenotypes CD44, CD24, CD44$^+$/CD24$^-$, CD44$^+$/CD24$^+$ in groups

Marker	Expression	Absolute value (%)		p
		Group 0 (n = 52)	Group 1 (n = 54)	
CD24	−	34 (65.4)	27 (50.0)	0.16
	+	18 (34.6)	27 (50.0)	
CD44	−	31 (59.6)	22 (40.7)	0.08
	+	21 (40.4)	32 (59.3)	
CD44$^+$/CD24$^-$	−	40 (76.9)	32 (59.3)	0.08
	+	12 (23.1)	22 (40.7)	
CD44$^+$/CD24$^+$	−	39 (75.0)	38 (70.4)	0.48
	+	9 (17.3)	7 (13.0)	
	++	3 (5.8)	8 (14.8)	
	+++	1 (1.9)	1 (1.8)	

In the distribution of the CSC putative marker, such as CD44$^+$/CD24$^-$, there was also a tendency (p = 0.08) to increase the level for patients after NACT. The expression of this immunophenotype was detected in 40.7% of cases after NACT and in 23.1% of cases in the primary tumour.

The coexpression of CD44$^+$/CD24$^+$ in the observed groups was also analyzed (Table 2) and there was approximately uniform absence of markers coexpression in both groups (75.0 and 70.4% of cases). High expression (2+ and 3+) of CD44$^+$/CD24$^+$ was detected in the tumour tissue after NACT more often (16.6%) than in the primary tumour (7.07%). Despite of revealed shift of CD44$^+$/CD24$^+$ statistically significant difference between the different groups of patients was not detected (p = 0.48). Thus, the data obtained in the research show a tendency to increase the expression of CD44$^+$ and CD44$^+$/CD24$^-$ (p = 0.08) in tumour tissue of breast in patients after NACT.

Survival analysis depending on clinical and pathological data and status of markers CD44, CD24, CD44$^+$/CD24$^-$, CD44$^+$/CD24$^+$. Univariate and multivariate analysis were performed in order to identify risks factors associated with survival. Cox proportional hazards regression model was used. In this model the categorical variables were clinical pathological data and the expression of the following specific cell surface markers: CD44, CD24, CD44$^+$/CD24$^-$, CD44$^+$/CD24$^+$.

Cox regression model allowed estimating the influence of the following factor signs on the survival distribution: CD24 and CD44 expression (negative or positive), CD44$^+$/CD24$^-$, CD44$^+$/CD24$^+$ (negative or positive), age, tumour size (pT1, pT2, pT3 and pT4), lymph node status (negative and positive), disease stages and subtypes of BC. The analysis of Cox univariate model (Table 3) identified that survival is associated with coexpression of CD44$^+$/CD24$^+$ (p = 0.06, HR = 1.73; 95% CI 0.98−3.06) and tumour phenotype. A worse prognosis was for triple negative subtype of BC (p < 0.001, HR = 3.29; 95% CI 1.72−6.28) and HER2/neu expression subtype (p = 0.09, HR = 2.89; 95% CI 0.86−9.73).

Age, stage of disease, category T and N and NACT are not significant for survival in Cox univariate model. The differences in the expression of immunophenotypes CD44, CD24, CD44$^+$/CD24$^-$ also were not found (Table 3).

Table 3

Analysis Cox univariate model of survival prognosis depending on clinical and pathological data and expression of cell surface markers

Factor	Index, b ± m	p	HR (95% CI)
Group 1 *vs* 0	0.06 ± 0.28	0.84	1.06 (0.61−1.84)
Age	0.000 ± 0.014	0.97	1.00 (0.97−1.03)
CD24$^+$ *vs* CD24$^-$	−0.01 ± 0.28	0.98	0.99 (0.57−1.71)
CD44$^+$ *vs* CD44$^-$	−0.02 ± 0.28	0.95	0.98 (0.57−1.70)
CD44$^+$/CD24$^+$ + *vs* −	0.55 ± 0.29	0.06	1.73 (0.98−3.06)
CD44$^+$/CD24$^-$ + *vs* −	−0.24 ± 0.30	0.44	0.79 (0.44−1.42)
TNBC *vs* luminal	1.19 ± 0.33	<0.001	3.29 (1.72−6.28)
HER2(+) *vs* luminal	1.06 ± 0.62	0.09	2.89 (0.86−9.73)
Luminal B (HER2+) *vs* luminal	0.58 ± 0.51	0.34	1.79 (0.56−4.85)
Category T	0.20 ± 0.18	0.25	1.22 (0.86−1.74)
Category N − *vs* +	−0.04 ± 0.30	0.89	0.96 (0.53−1.73)

Results of Cox univariate analysis can be presented graphically (Figure).

Figure. Cox univariate model for survival analysis

Multivariate analysis of survival. We also have considered applying multivariate forecasting model, while objective estimation of prediction seldom depends on one isolated factor.

After the selection of significant features using the step-by-step inclusion/exclusion method (threshold of inclusion p < 0.2, exclusion threshold p > 0.4), a multivariate model of prognosis was constructed (Table 4).

Table 4

Cox multivariate model for survival analysis

Factor	Index, b ± m	p	HR (95% CI)
TNBC *vs* luminal	1.21 ± 0.33	< 0.001	3.4 (1.7−6.5)
HER2(+) *vs* luminal	0.99 ± 0.63	0.12	2.7 (0.8−9.3)
Luminal B (HER2+) *vs* luminal	0.45 ± 0.62	0.46	−
Category T	0.31 ± 0.19	0.10	1.4 (0.9−2.0)
CD44$^+$/CD24$^+$ + *vs* −	0.47 ± 0.30	0.12	1.6 (0.9−2.9)

In the multivariate model, TN subtype of BC was the only significant prognostic variable which influenced on survival (p < 0.001, HR = 3.4; 95% CI 1.7−6.5). Nevertheless, the factors that influence on survival indirectly were also HER2/neu expression subtype (p = 0.12, HR = 2.7; 95% CI 0.8−9.3), luminal B (HER2+) positive subtype (p = 0.46), coexpression of CD44$^+$/CD24$^+$ (p = 0.12, HR = 1.6; 95% CI 0.9−2.9) and category T. It was revealed that the increase in tumour size resulted deterioration of survival (p = 0.12; HR = 1.6; 95% CI 0.9−2.09).

In the research we show that clinical and morphological features of patients of BC are different in groups having operative treatment immediately or NACT before surgery. It is known that chemotherapy has the selectivity for proliferating cells and how much chemotherapy acts on the clone of stem cells capable to be predictors of drug resistance and poor prognosis is still being studied [14].

We have found variable patterns of markers' expression in different tumour samples. Our data are consistent with some previously observed trends — an increase of the number of CD44+ and CD44+/CD24− in tumour tissue after NACT [25]. We have noticed that CD44 was markedly expressed in tumour tissue of breast after NACT, which indicates that CD44 is involved in tumorigenesis of BC. This result coincides with the data: CD44+ shows a more mesenchymal, mobile and less proliferative profile and is similar to stem cells [26]. An increase of CD44+ expression after chemotherapy may indicate the development of resistance to cytostatics [14, 27].

The same tendency in the expression of CD44+/CD24− tumour cells was noted in patients after NACT (p = 0.08). This shift of CD44+/CD24− was probably due to increase in the subpopulation of CD44+. The profile of CD44+/CD24− was previously widely investigated and their invasive nature was proved. It made this population possible CSC [9, 16]. The fact that a small population of CSC survives after chemotherapy and causes the relapse of invasive BC [28] is still interesting for many researchers. It was stressed in some articles that CD44+/CD24−/low cells demonstrate properties of CSC and chemoresistance [29] and CD24− cells enhance the resistance to doxorubicin [13]. The content of another cell surface marker, CD24, did not differ in tumour tissue of both groups in our research. Although the predictive significance of CD24 cells after NACT in patients with BC was previously reported by other researchers [22], and in particular the stability of CD24−/low cells to the treatment of anthracyclines was mentioned [13].

Thus, analysis of cell surface markers expression revealed the differences between groups with a tendency to a significant increase of CD44+ and CD44+/CD24− in tumour tissue of breast after NACT, which may play a certain role in the development of resistance to chemotherapy and in the possible mechanism of relapse after treatment.

We estimated the prognostic value of clinical-pathological indicators and cell surface markers CD24, CD44. We noticed that the TNBC showed a poor prognosis for survival, which corresponds to the previous investigations [30]. The trend towards a significant effect of the HER2/neu expression subtype on the survival in the univariate analysis has lost its significance in the Cox multivariate analysis. But the increase in tumour size resulted deterioration of survival in multivariate analysis.

In the Cox univariate and multivariate analysis we did not find any relationship between age, disease stage, lymph node involvement, NACT, CD44, CD24, CD44+/CD24− expression and clinical outcome — survival. Our data coincide with the research result [11] that there is no link between the status of CD44+/CD24− and survival.

However, according to other scientists' investigations, CD44+/CD24− tumour cells were significantly associated with poor survival [10], CD24 expression was a marker of poor prognosis for the luminal A subtype [31]. It was also shown that negative CD24 tumours have a very low risk of tumour progression, while CD24 positive tumours are associated with a short-term DFS [17]. Some researchers note that high expression of CD44 correlates with reduced DFS and the existence of distant metastases [13, 21, 32], other scientists [22] — on the contrary, emphasize that CD44+ contributes to a favourable prognosis in patients with primary BC.

In our study, one of the prognostic factors was tumour cells with coexpression of CD44+/CD24+, which showed a tendency to a significant effect on survival in the univariate analysis. Presented data show that non-invasive CD44+/CD24+ cells are plastic and can easily generate offspring of invasive CD44+/CD24− cells through activation of signalling Activin/Nodal [27]. The hypothesis of the variable existence of tumour cells, which are either CD44+ or CD24+, can reflect the current state of tumour with undergoing constant cell renewal, differentiation and interaction with the surrounding stroma [11]. It is permissible that CD44+ and CD24+ cells can undergo the independent clonal evolution [26] and thereby it emphasizes the biological heterogeneity of BC.

CONCLUSION

Research results underline biological intratumoral heterogeneity of BC and demonstrate different expression of CD44, CD24 in tumour tissue of the primary BC and in samples after NACT. The investigated cell surface markers can undergo certain changes after NACT and, possibly, can increase resistance to the chemotherapy. CD44 and CD24 are markers associated with carcinogenesis in BC, but in our research they were insufficient factors to determine the prognosis.

Further investigations are necessary to determine the place and role of CD24, CD44 in chemoresistance and prognosis of patients of BC.

REFERENCES

1. **Eisemann N, Waldmann A, Katalinic A.** Epidemiology of breast cancer — current figures and trends. Geburtshilfe Frauenheilkd 2013; **73** (2): 130−5.

2. **Thiery JP, Acloque H, Huang RY, Nieto MA.** Epithelial-mesenchymal transitions in development and disease. Cell 2009; **139** (5): 871−90.

3. **Bensimon J, Altmeyer-Morel S, Benjelloun H, et al.** CD24(-/low) stem-like breast cancer marker defines the radiation-resistant cells involved in memorization and transmission of radiation-induced genomic instability. Oncogene 2013; **32** (2): 251−8.

4. **Dean M, Fojo T, Bates S.** Tumour stem cells and drug resistance. Nat Rev Cancer 2005; **5** (4): 275−84.

5. **Baumann P, Cremers N, Kroese F, et al.** CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 2005; **65** (23): 10783−93.

6. **Blacking TM, Waterfall M, Argyle DJ.** CD44 is associated with proliferation, rather than a specific cancer stem cell population, in cultured canine cancer cells. Vet Immunol Immunopathol 2011; **141** (1−2): 46−57.

7. **Camerlingo R, Ferraro GA2, De Francesco F, et al.** The role of CD44+/CD24−/low biomarker for screening, diagnosis and monitoring of breast cancer. Oncol Rep 2014; **31** (3): 1127−32.

8. **Abraham BK, Fritz P, McClellan M, et al.** Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005; **11** (3): 1154—9.

9. **Sheridan C, Kishimoto H, Fuchs RK, et al.** CD44+/CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006; **8** (5): R59.

10. **Idowu MO, Kmieciak M, Dumur C, et al.** CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 2012; **43** (3): 364—73.

11. **Honeth G, Bendahl PO, Ringnér M, et al.** The CD44+/CD24− phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008; **10** (3): R53.

12. **Chekhun SV, Zadvorny TV, Tymovska YO, et al.** CD44+/CD24− markers of cancer stem cells in patients with breast cancer of different molecular subtypes. Exp Oncol 2015; **37** (1): 58—63.

13. **Deng X, Apple S, Zhao H, et al.** CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer. Oncotarget 2017; **8** (24): 38294—308.

14. **Yenigun VB, Ozpolat B, Kose GT.** Response of CD44+/CD24−/low breast cancer stem/progenitor cells to tamoxifen- and doxorubicin-induced autophagy. Int J Mol Med 2013; **31** (6): 1477—83.

15. **Lee JH, Kim SH, Lee ES, Kim YS.** CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep 2009; **22** (5): 1149—56.

16. **Al-Hajj M, Wicha MS, Benito-Hernandez A, et al.** Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; **100** (7): 3983—8.

17. **Kristiansen G, Winzer KJ, Mayordomo E, et al.** CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003; **9** (13): 4906—13.

18. **Kwon MJ, Han J, Seo JH, et al.** CD24 overexpression is associated with poor prognosis in luminal a and triple-negative breast cancer. PLoS One 2015; **10** (10): e0139112.

19. **Jang MH, Kang HJ, Jang KS, et al.** Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer. Oncol Lett 2016; **12** (4): 2728—33.

20. **Hosonaga M, Arima Y, Sugihara E, et al.** Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells. Cancer Sci 2014; **105** (7): 779—87.

21. **Xu H, Wu K, Tian Y, et al.** CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer. Int J Oncol 2016; **49**(4): 1343—50.

22. **Horiguchi K, Toi M, Horiguchi S, et al.** Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients. J Med Dent Sci 2010; **57** (2): 165—75.

23. **Ryspayeva DE, Smolanka II, Dudnichenko AS, et al.** Are CD44(+)/CD24(-) cells the assumed cancer stem cells in breast cancer? Exp Oncol 2017; **39** (3): 224—8.

24. **Carey LA, Perou CM, Livasy CA, et al.** Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; **295** (21): 2492—502.

25. **Li X, Lewis MT, Huang J, et al.** Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; **100** (9): 672—9.

26. **Shipitsin M, Campbell LL, Argani P, et al.** Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; **11** (3): 259—73.

27. **Meyer MJ, Fleming JM, Ali MA, et al.** Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res 2009; **11** (6): R82.

28. **Fillmore CM, Kuperwasser C.** Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; **10** (2): R25.

29. **Ge G, Zhou C, Ren Y, et al.** Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling. Tumour Biol 2016; **37** (4): 5049—62.

30. **Choi YL, Oh E, Park S, et al.** Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer 2010; **10**: 507.

31. **de Mascarel I, Debled M, Brouste V, et al.** Comprehensive prognostic analysis in breast cancer integrating clinical, tumoral, micro-environmental and immunohistochemical criteria. Springerplus 2015; **4**: 528.

32. **McFarlane S, Coulter JA, Tibbits P, et al.** CD44 increases the efficiency of distant metastasis of breast cancer. Oncotarget 2015; **6** (13): 11465—76.

ПРЕДИКТИВНИЙ І ПРОГНОСТИЧНИЙ ПОТЕНЦІАЛ ЕКСПРЕСІЇ CD44 І CD24 У ПЕРВИННІЙ ПУХЛИНІ ТА ПІСЛЯ ХІМІОТЕРАПІЇ У ПАЦІЄНТІВ З РАКОМ МОЛОЧНОЇ ЗАЛОЗИ

Д.Е. Риспаєва

Національний інститут раку МОЗ України, Київ, Україна

Резюме. *Мета: оцінити прогностичне і предиктивне значення маркерів CD44 і CD24 у первинній пухлині та після проведення неоад'ювантної хіміотерапії (НАХТ) у різних групах хворих на рак молочної залози (РМЗ). Об'єкт і методи: зразки тканини пухлин 106 хворих на інвазивний РМЗ, які проходили лікування в Національному інституті раку. Експресію маркерів CD44 і CD24 визначали за допомогою імуногістохімічного методу. Проведено аналіз виживаності пацієнтів залежно від клініко-патологічних даних і експресії CD44, CD24, CD44+/CD24−, CD44+/CD24+. Результати: виявлено відмінності в експресії досліджуваних маркерів у первинній пухлинній тканині та після проведення НАХТ. Підвищення експресії CD44+ і CD44+/CD24− у пухлинній тканині після проведення НАХТ може відігравати певну роль у формуванні хіміорезистентності та можливому механізмі розвитку рецидиву інвазивного РМЗ. За допомогою регресивної моделі Кокса виявлено прогностичне значення тричі негативного підтипу РМЗ, розміру пухлини, коекспресії неінвазивних клітин CD44+/CD24+. Висновок: відмінність експресії поверхневих клітинних маркерів у первинній пухлині та після проведення НАХТ відображає внутрішньопухлинну гетерогенність РМЗ та, можливо, ймовірність розвитку хіміорезистентності. Прогностичними факторами, які пов'язані з виживаністю, виявилися тричі негативний підтип та розмір пухлини. Рівні експресії маркерів CD44 і CD24 виявилися недостатніми факторами для визначення прогнозу.*

Ключові слова: рак молочної залози, стовбурові пухлинні клітини, CD44, CD24, виживаність, хіміотерапія, прогностичне значення.

Correspondence:
Ryspayeva D.E.
33/43 Lomonosova str., Kyiv 03022, Ukraine
National Cancer Institute, MH of Ukraine
E-mail: ryspayeva1@gmail.com